Fig. 6: In vivo TFV-DP Measurements. | Nature Communications

Fig. 6: In vivo TFV-DP Measurements.

From: Transformation of tenofovir into stable ProTide nanocrystals with long-acting pharmacokinetic profiles

Fig. 6

SD rats were administered a single IM dose of NM1TFV (green), NM2TFV (orange), or NTAF (blue) (75 mg/kg TFV-eq.) to determine pharmacokinetic (PK) profiles. a TFV-DP concentrations in PBMCs were determined at days 1 and 14 then every two weeks for 8 weeks. Tissue biodistribution of TFV-DP was assessed at 28 and 56 days after injection in the b lymphocytes (**P = 0.0024, NM2TFV vs. NTAF), c splenocytes, d parenchymal liver cells (*P = 0.0372, NM1TFV vs. NM2TFV), e non-parenchymal liver cells, f rectal tissue (*P = 0.0115, **P = 0.0058 NM1TFV vs. NM2TFV), and g vaginal tissue. Data are expressed as mean ± SEM where N = 4 biological replicates. Vaginal TFV-DP concentrations were compared using a two-tailed unpaired t-test (****P < .0001, ***P < .001, **P < .01, *P < .05 NM1TFV compared with NM2TFV). a−f To compare TFV-DP levels between three or more groups, ordinary one-way ANOVA followed by Tukey’s post hoc test with a single pooled variance (****P < .0001, ***P < .001, **P < .01, *P < .05 NM1TFV compared with NM2TFV).

Back to article page